Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Ex Input:
Paragraph: The release does not mention cost. The FDA evaluates drugs without consideration of cost, so it's understandable that they wouldn't comment on it and that's why we're rating this Not Applicable. But let's be real here: The value of a new drug is a function not just of how well it works, but its cost-effectiveness. So we look forward to the day when any news release about a new drug even one from the FDA will include some mention of cost in its message. This release gives the preliminary results from a single study of 310 patients. Because the drug is experimental, long-term results haven't been studied. Of the 310 patients enrolled in the lone trial upon which the approval is based, 14.8 percent showed some shrinkage of tumors during the assessment period lasting from 2.1 to about 13.8 months. For a subset of patients who were classified as having a positive response to PD-L1 expression, the response was 26 percent. As noted above, tumor shrinkage doesn't always lead to improvements in survival or quality of life. It is a surrogate endpoint a substitute for the main outcome which is survival. Although this drug looks promising, to be fully transparent about its benefits as currently known, the release should have explained this. As noted in the "Summary," another larger study is underway to assess the drug's impact on extending life and improving quality of life. The release includes a description of side effects of this treatment. The most common ones included fatigue, decreased appetite, nausea, urinary tract infection, fever (pyrexia) and constipation. The release also mentions that patients taking the drug have an increased risk of infection and serious side effects that are "immune-mediated." We would have liked a bit more context on what this term means for patients. The release outlines that this is the very first clinical trial of this compound for safety and efficacy, and under which regulatory paths the drug was assessed, including "breakthrough therapy designation, priority review status and accelerated approval." We're giving this release the benefit of the doubt and rating it Satisfactory for its bare bones description of the trial (and since we already addressed the lack of long-term survival data in the "Benefits" section.) As it stands, the results from the small trial were preliminary and short-term and did not reflect long-term survival. We would have liked to see a reference or link to the completed trial where one could look at the results to assess independently or learn more about the outcomes. We think the release should have provided more data on the patient demographics, the treatment regimen (dosing amount and schedule) as well as the range in tumor reduction. There is no disease mongering. This release describes the approval of a new drug by a regulatory agency, but we'd still like to know who sponsored the study that's the basis for the approval. It's not enough to state who markets the drug. The release does not give us very much information about alternatives. These patients had already received other therapy and their cancer had recurred, so it is implied that they had no other alternatives. But this isn't stated very clearly. We can assume (and it seems evident) that the platinum-based therapy that the patients didn't respond to initially is the usual treatment. The FDA's approval of a drug clears the way for the drug sponsor to scale up production and begin marketing and selling the product. (The FDA doesn't state this explicitly but it can be inferred.) A NYT article said the drug would be available in about two months. The release clearly states this product is first of its kind for this type of cancer. We found no unjustifiable language. Claim: FDA approves new, targeted treatment for bladder cancer

Ex Output:
The Food and Drug Administration approved a new immunotherapy drug that acts as a "checkpoint" inhibitor in patients whose bladder cancer (urothelial carcinoma) has not responded to other chemotherapy. The drug, atezolizumab (marketed as Tecentriq), showed effectiveness in about 14 percent of 310 patients in a very preliminary study. The release notes that the trial measured tumor shrinkage as the main outcome. It didn't note, as a NYT article did, and important for this type of trial, that it is unknown whether the treatment makes a difference in survival. A larger study is being done to examine this. Whether it makes a difference in quality of life is also important and will presumably be examined in the larger trial. The National Cancer Institute (NCI) estimates 76,960 new cases of bladder cancer and 16,390 deaths from this disease in 2016. This approval of a new drug for treating bladder cancer is part of a wider area of research into immunotherapy, in which drugs target mechanisms of the human immune response. Patients with the PD-L1 protein highly expressed in their tumors appear to be responding best to the drug. This drug is an example of targeted chemotherapy which is becoming more important as treatments can be fine-tuned to the cancers of individual patients. In patients with intractable cancers, immunotherapy appears to offer some new hope while also bringing sobering questions about affordability and disparity of access by income. The drugs are typically very expensive with some estimates putting the treatment cost for a single patient as high as $1 million. When the FDA gives a compound a "breakthrough" designation, some physicians and patients can misunderstand what that means. That's a topic recently explored in this post.

Ex Input:
Paragraph: The governor, who is also a pediatric neurologist, worked to comfort victims of Friday's shooting and their families, while helping coordinate the massive government response. He discussed the shooting with President Donald Trump in a private phone call, stood shoulder to shoulder with other elected officials at a news conference and pressed for tighter gun control to national audiences. The subject of widespread mockery after the racist photo from his medical school yearbook surfaced, the Democratic governor appears determined to project that he's up to the task. "Actions speak a lot louder than words. And I will have the leadership that's needed," Northam said in an interview with NPR after the shooting, while discussing potential plans to push for increased gun regulations. Police said 12 people were killed and several others injured when DeWayne Craddock, an engineer with the city's utilities department, opened fire inside a municipal building Friday afternoon. Northam quickly left Richmond after the shooting and drove to Virginia Beach, speaking to local, state and other officials on the way down to coordinate responses and share information. After a news conference Friday evening, Northam took a call from Trump to discuss the shooting, with the president offering the federal government's full support. Michael Berlucchi, a Virginia Beach City Council member, praised the governor and other officials for their work to address the shooting's aftermath from the city's emergency operations center. "Nobody carried their baggage into that room," Berlucchi said Sunday. "The only thing I saw was public servants coming together to address the worst tragedy in the history of our city." On Saturday, Northam attended a vigil at a church where he told those gathered that "God is in control." He visited a hospital to meet with survivors and thank doctors and staff. In broadcast interviews with national media, Northam stressed the need for action to prevent similar deadly shootings. "We lost 12 lives yesterday. If you look at the commonwealth of Virginia, we lost over 900 lives over the past two years to gun violence, gun-related accidents," Northam said on CNN. "So I will make decisions in the upcoming days but we need to look at our laws: are they safe, do they keep people protected in the Commonwealth of Virginia?" The governor has long been an advocate for stricter gun control. He made the issue a top priority of his 2017 gubernatorial campaign, drawing from his experience as a pediatrician and Army doctor who has treated children and soldiers wounded by firearms. But a package of bills Northam pushed this year, including legislation to limit gun magazine size and give local governments broader authority to ban guns in city buildings, went nowhere in a staunchly pro-gun Republican-controlled Virginia General Assembly. Northam hinted Saturday in media interviews that he may be considering some kind of executive action related to gun control efforts that would bypass the legislature, but his office declined to say what specific actions he may take. Any dramatic moves by the governor would face stiff resistance from his political opponents. Philip Van Cleave, president of the Virginia Citizens Defense League, said Northam doesn't have any real power to impose new gun limits and any efforts to do so would be an attempt to deflect attention away his scandal. "He'd be very happy to try and change the focus away from the blackface stuff," Van Cleave said. Northam has been battling for months to regain a sense of normalcy in office after a picture surfaced in February of man in blackface and another person wearing a Ku Klux Klan outfit on his medical school yearbook page. Northam has denied being in the picture, and investigators recently said they can't conclusively establish the identities of either person in the 35-year-old photo. The governor withstood widespread pressure for him to resign, which weakened after scandal soon enveloped his potential successors . Two women publicly accused Lt. Gov. Justin Fairfax of sexual assault, which he denies, and Attorney General Mark Herring announced he'd also worn blackface in college, just days after calling on Northam to resign. Both Fairfax and Herring have also resisted calls to resign. Fairfax was also in Virginia Beach after the shooting. He attended a church service Sunday where and pledged to take "serious action" to prevent future mass shootings. "I think that thoughts and prayers from politicians are not enough," Fairfax said. "We've had too many thoughts and prayers over the years and we've not acted in the ways to prevent these mass shootings in the future." ___ This story has been corrected to say pediatrician, not pedestrian. ___ Contributors include Associated Press writer Ben Finley. Claim: Shooting poses Virginia governor's first test since scandal.

Ex Output:
Virginia Gov. Ralph Northam wasted little time getting to Virginia Beach after a gunman killed a dozen people in a city office building, the first major test of his leadership since a blackface scandal almost forced him from office four months ago.

Ex Input:
Paragraph: In May 2020, The New York Times reported that Asian giant hornets, often referred to as "murder hornets," had been spotted for the first time in the United States. This was not welcome news, and social media sites quickly filled up with alarming images of these large insects. One such photograph supposedly showed four "murder hornets" in the palm of a person's hand: This is a genuine photograph of Asian giant hornets. A 2010 article from National Geographic described these hornets as "small but highly efficient killing [machines]" that were approximately 2 inches long with a 3-inch wingspan. Although people have died from this hornet's painful sting, the insects are only "highly efficient killing machines" when it comes to bees. National Geographic wrote: Bees, other hornet species, and larger insects such as praying mantises are no match for the giant hornets, which often stalk their prey in relentless armies. Just one of these hornets can kill 40 European honeybees a minute; a handful of the creatures can slaughter 30,000 European honeybees within hours, leaving a trail of severed insect heads and limbs. People are not the Japanese giant hornet's usual prey, but those who have felt its sting describe the pain as excruciating. Masato Ono, an entomologist at Tamagawa University, near Tokyo, said it's "like a hot nail through my leg." Someone who is stung by the hornet and doesn't receive proper treatment soon thereafter can die from the venom, which is powerful enough to disintegrate human flesh. About 40 people die each year after being stung by giant hornets, mainly as a result of an allergic reaction to the venom. The above-displayed photograph was taken in 2011 by Devon Henderson and shows four dead Asian giant hornet queens in the palm of the photographer's hand. This image was originally posted to Henderson's Flickr account dedicated to Hymenoptera, a large order of insects which includes wasps, bees, and ants. Claim: A photograph shows four Asian giant hornets barely fitting on the palm of someone's hand.

Ex Output:
Henderson noted in the comments that these bugs were all deceased (she acquired the bugs from a website called Insect-Sale) and that queen Japanese giant hornets, a colored variant of the Asian giant hornet, were 40-45 millimeters long (approximately 1.75 inches).